1. World Health Organization. Schizophrenia—fact sheet. 2018.
http://www.who.int/news-room/fact-sheets/detail/schizophrenia
. Accessed 14 Aug 2018.
2. World Health Organization. The world health report 2001: mental health: new understanding, new hope. 2018.
http://www.who.int/whr/2001/en/whr01_en.pdf
. Accessed 14 Aug 2018.
3. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988;244(2):685–93.
4. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
5. Bo Q-J, Li X-B, Wang Z-M, Li A-N, Ma X, Wang C-Y. Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study. J Clin Psychopharmacol. 2016;36(2):125–9.